SCHEMBL23459205

SCHEMBL23459205

CCOc1cc(-c2ccc(F)cc2)c(Br)cc1CO

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.39
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
MAPK1 P28482 3/20 0.39
HSD17B10 Q99714 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C19 P33261 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
S1PR1 P21453 3/20 0.37
POLB P06746 2/20 0.37
S1PR3 Q99500 1/20 0.37
TP53 P04637 1/20 0.37
LMNA P02545 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
GAA P10253 2/20 0.37
FFAR4 Q5NUL3 1/20 0.37
LTB4R Q15722 1/20 0.37
LTB4R2 Q9NPC1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23459351 0.87 L3MBTL1 (0.37) MAPTMEN1KMT2AMAPK1HSD17B10
SCHEMBL16616309 0.79 SSTR5 (0.49) MAPTLMNAFFAR4NR3C1SSTR5
SCHEMBL16616252 0.78 SLC6A3 (0.50) MAPTMEN1KMT2AHSD17B10CYP1A2
SCHEMBL7797903 0.76 TSHR (0.43) MAPTMEN1KMT2AMAPK1HSD17B10
SCHEMBL20562654 0.75 HSD17B10 (0.44) MAPTMEN1KMT2AMAPK1HSD17B10
SCHEMBL16960532 0.75 MAPK1 (0.43) MAPTMAPK1HSD17B10L3MBTL1CYP1A2
SCHEMBL19859187 0.75 L3MBTL1 (0.42) MAPTMEN1KMT2AMAPK1L3MBTL1
SCHEMBL23459421 0.74 ALDH1A1 (0.44) MEN1KMT2AMAPK1POLBNPSR1
SCHEMBL23586689 0.73 TSHR (0.41) MAPTMEN1KMT2AMAPK1HSD17B10
SCHEMBL3097800 0.72 SSTR5 (0.48) MAPTMEN1KMT2AMAPK1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230050965-A1 SSTR5 ANTAGONISTS KALLYOPE, INC. 2023-02-16 US disclosed
EP-4069708-A1 SSTR5 ANTAGONISTS Kallyope, Inc. (US) 2022-10-12 EP disclosed
WO-2021113363-A1 SSTR5 ANTAGONISTS KALLYOPE, INC. (US) 2021-06-10 WO disclosed
WO-2021113363-A1 SSTR5 ANTAGONISTS KALLYOPE, INC. (US) 2021-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230050965-A1 SSTR5 ANTAGONISTS SSTR5, GLP1R, GPR119 MAPT 1483/4885MEN1 2406/4885KMT2A 2300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.